Home

Bio Innovation Is Our Mission

We are a phar­ma­ceu­ti­cal biotech­nol­o­gy com­pa­ny focus­ing on anti­body and bac­te­rio­phage ther­a­pies to address unmet med­ical needs.

Our cut­ting-edge research aims to devel­op nov­el treat­ments for resis­tant microor­gan­isms that cause com­plex dis­eases and infec­tions, pro­vid­ing new hope for patients.

Con­tact Us
Focus Areas
Focus Areas
Oph­thal­mol­o­gy Dia­bet­ic Retinopa­thy
Ocu­lar Sur­face Infec­tion
Der­ma­tol­ogy Atopic Der­mati­tis
Oncol­o­gy Sol­id Tumors
Infec­tious dis­eases Dia­bet­ic Foot Infec­tion

Our Technology

Bacteriophage for AMR Therapeutics

Bac­te­rio­phage ther­a­peu­tics pro­vide a tar­get­ed approach against antimi­cro­bial resis­tance, pre­cise­ly elim­i­nat­ing pathogens.

Dis­cov­er More

Anti-VEGF in Nanoparticles

Eye­drops Anti-VEGF anti­body encap­su­lat­ed in nanopar­ti­cles enables tar­get­ed, sus­tained drug deliv­ery for treat­ing reti­nal dis­eases.

Dis­cov­er More

Phage-based Delivery Systems

Based on a mod­u­lar archi­tec­ture built on a bac­te­rio­phage fil­a­men­tous, enabling next gen­er­a­tion tar­get­ed deliv­ery of bio­log­ics and con­ven­tion­al small-mol­e­cule drugs.

Dis­cov­er More

Biologics R&D Unit

Anti­body and CAR‑T cell R&D ser­vices span dis­cov­ery to pre­clin­i­cal opti­miza­tion, accel­er­at­ing immunother­a­py devel­op­ment.

Dis­cov­er More

Partner with us

Found­ed in 2021, Lxbio Phar­ma­ceu­ti­cals is a Por­tuguese bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive ther­a­peu­tic plat­forms address­ing major unmet
med­ical needs across Oncol­o­gy, Infec­tious Dis­eases, Oph­thal­mol­o­gy, Der­ma­tol­ogy, and oth­er com­plex indi­ca­tions.

With a diver­si­fied, inno­va­tion-dri­ven pipeline and an inde­pen­dent val­u­a­tion exceed­ing €100 mil­lion, Lxbio reflects strong investor con­fi­dence in its sci­en­tif­ic
plat­forms, lead­er­ship, and exe­cu­tion capa­bil­i­ty. Dis­cov­er More

Carlos Paula

Lxbio, CEO

At Lxbio Phar­ma­ceu­ti­cals, inno­va­tion goes hand in hand with respon­si­bil­i­ty. We are com­mit­ted to advanc­ing break­through biotech­nol­o­gy while uphold­ing the high­est stan­dards of ethics, com­pli­ance, and ESG gov­er­nance.

Our work is guid­ed by a strong com­mit­ment to soci­ety, sus­tain­abil­i­ty, and respon­si­ble inno­va­tion, ensur­ing that sci­en­tif­ic progress trans­lates into mean­ing­ful ben­e­fits for patients and com­mu­ni­ties.

We also fos­ter a cul­ture of diver­si­ty, equi­ty, and inclu­sion, rec­og­niz­ing that diverse per­spec­tives dri­ve bet­ter sci­ence and stronger inno­va­tion.

Togeth­er, these prin­ci­ples shape our mis­sion to build Lxbio into a glob­al­ly respon­si­ble for next-gen­er­a­tion ther­a­peu­tics.

Latest News